![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Assessment of risk of acute kidney injury associated with exposure to sofosbuvir-containing HCV treatment regimens and HCV infection
|
|
|
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
L Telep, A Brown, DM Brainard, AP Chokkalingam
Gilead Sciences, Inc., Foster City, CA, United States
![HIV1](../images/112116/112116-11/HIV1.gif)
![HIV2](../images/112116/112116-11/HIV2.gif)
![HIV3](../images/112116/112116-11/HIV3.gif)
![HIV4](../images/112116/112116-11/HIV4.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|